Package Leaflet: Information for the User
VIMOVO 500mg/20mg modified-release tablets
naproxen and esomeprazol
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is VIMOVO
VIMOVO contains two different medicines called naproxen and esomeprazol. Each of these medicines works in a different way.
Esomeprazol helps to reduce the risk of ulcers and stomach problems that can occur in patients who need to take NSAIDs.
What is VIMOVO used for
VIMOVO is used in adults for the relief of symptoms of:
VIMOVO helps to reduce pain, swelling, redness, and heat (inflammation).
You will receive this medicine if it is considered unlikely that a lower dose of an NSAID will relieve your pain and you are at risk of developing a stomach ulcer or an ulcer in the first part of the small intestine (duodenum) while taking an NSAID.
Do not take VIMOVO:
Do not take VIMOVO if you are in any of the above situations. If you are not sure, consult your doctor or pharmacist before taking VIMOVO.
Warnings and precautions
Consult your doctor or pharmacist before starting to take VIMOVO.
Do not take VIMOVO and consult your doctor immediately if you experience any of the following episodes before or during treatment with VIMOVO, as this medicine may mask the symptoms of another illness:
If you are in any of these situations (or are unsure), consult your doctor or pharmacist before taking this medicine.
Consult your doctor or pharmacist before taking this medicine if:
If you are in any of these situations (or are unsure), consult your doctor or pharmacist before taking this medicine.
If you have had a stomach ulcer or bleeding before, inform your doctor. You will be asked to inform your doctor of any unusual stomach symptoms (e.g. pain).
Some medicines like VIMOVO may be associated with a small increased risk of heart attack (myocardial infarction) or stroke. The risk is always greater with higher doses and longer treatment. Do not exceed the recommended dose or duration of treatment.
VIMOVO contains the NSAID naproxen. As with all NSAIDs, naproxen should be used at the lowest effective dose with the shortest possible treatment duration to reduce the risk of unwanted effects. Your doctor will therefore regularly assess whether VIMOVO is still suitable for you.
VIMOVO is not suitable for rapid relief of acute pain, as it takes several hours for the analgesic naproxen to reach the bloodstream.
Consult your doctor before taking this medicine if you have any heart problems, a history of stroke, or think you are at risk of these problems. You may be at risk of these problems if:
Taking a proton pump inhibitor (which is one of the components of VIMOVO), especially for more than a year, may slightly increase the risk of fractures of the hip, wrist, or spine. Inform your doctor if you have osteoporosis or are taking corticosteroids (which may increase the risk of osteoporosis).
If you experience a skin rash, especially in areas of the skin exposed to the sun, consult your doctor as soon as possible, as it may be necessary to interrupt treatment with VIMOVO. Remember to mention any other symptoms you may notice, such as joint pain.
Severe skin rashes have occurred in patients taking esomeprazol (see also section 4). The rash may include ulcers in the mouth, throat, nose, genitals, and conjunctivitis (red and swollen eyes). These severe skin rashes usually occur after symptoms similar to those of the flu, such as fever, headache, and body aches. The rash may cover large areas of the body with blisters and peeling skin.
If at any time during treatment (even after several weeks) you develop a rash or any of these skin symptoms, stop taking this medicine and contact your doctor immediately.
During treatment with VIMOVO, kidney inflammation may occur. The signs and symptoms may include decreased urine volume or blood in the urine and/or hypersensitivity reactions such as fever, skin rash, and joint stiffness. You should inform your doctor of these signs.
Children and adolescents
VIMOVO is not recommended for use in children or adolescents under 18 years of age.
Taking VIMOVO with other medicines
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription, including herbal medicines. This is because VIMOVO may affect the way other medicines work. There are also some medicines that may affect the way VIMOVO works.
Do not take this medicine and inform your doctor or pharmacist if you are taking:
Inform your doctor or pharmacist if you are taking any of these medicines:
If you are in any of these situations (or are unsure), consult your doctor or pharmacist before taking VIMOVO.
Taking VIMOVO with food and drinks
Do not take VIMOVO with food, as it may reduce and/or delay the effect of VIMOVO. Take the tablets at least 30 minutes before meals.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take VIMOVO if you are in the last 3 months of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in the fetus. It may affect bleeding tendency, yours and your baby's, and that delivery may be delayed or prolonged more than expected. You should not use VIMOVO during the first 6 months of pregnancy unless it is absolutely necessary and your doctor advises you to do so. If you need treatment during this period or while trying to become pregnant, you should use the lowest dose for the shortest possible time. If you take it for more than a few days from the 20th week of pregnancy, VIMOVO may cause kidney problems in the fetus that can lead to low levels of the fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need to prolong treatment for more than a few days, your doctor may recommend additional monitoring.
Breastfeeding
Do not breastfeed if you are taking VIMOVO, as small amounts may pass into breast milk. If you are planning to breastfeed, do not take VIMOVO.
Fertility
VIMOVO may make it harder for you to become pregnant. You should inform your doctor if you are planning a pregnancy or are having difficulty becoming pregnant.
Driving and using machines
You may feel dizzy or experience blurred vision during treatment with VIMOVO. If this happens, do not drive or use tools or machines.
VIMOVO containsmethyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)
These ingredients may cause allergic reactions. These reactions can be delayed.
VIMOVO contains less than 1 mmol of sodium (23mg) per tablet, i.e., it is essentially “sodium-free”.
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
How to take this medicine
How much to take
If you take more VIMOVO than you should
If you take more VIMOVO than you should, consult your doctor or pharmacist immediately. The symptoms of an overdose may include lethargy, dizziness, drowsiness, abdominal pain and/or discomfort, heartburn, indigestion, nausea, liver problems (which can be seen in a blood test), kidney problems that can be severe, high levels of acid in your blood, disorientation, vomiting, stomach or intestinal bleeding, high blood pressure, breathing difficulties, coma, sudden allergic reactions (which can include shortness of breath, skin rashes, swelling of the face and/or throat, and/or collapse), and uncontrolled body movements.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take VIMOVO
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. The following adverse effects may occur with this medicine.
Stop taking VIMOVO and consult a doctor immediately if you notice any of the following serious adverse effects - you may need urgent medical treatment:
Tell your doctor as soon as possible if you experience any of the following symptoms:
In rare cases, VIMOVO may affect the white blood cells in the blood, leading to immunosuppression.
If you have an infection with symptoms such as fever with a severe worsening of your general health or fever with symptoms of local infection such as neck, throat, or mouth pain or difficulty urinating, you should consult your doctor as soon as possible to rule out a lack of white blood cells (agranulocytosis) through a blood test. It is essential that you report your medication at that time.
Other adverse effects are:
Common (may affect up to 1 in 10 people)
Uncommon, rare, or very rare (may affect up to 1 in 100 people or less)
Frequency not known (cannot be estimated from available data)
Do not worry about this list of possible adverse effects.You may not experience any of them.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Medicines Agency: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging, bottle, or blister after CAD. The expiration date is the last day of the month indicated.
Do not store above 30°C.
Bottle: Keep this medicine in its original packaging and keep the bottle tightly closed to protect it from moisture.
Blister: Keep this medicine in its original packaging to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of VIMOVO
Appearance of the product and package contents
Oval tablets, 18x9.5 mm, yellow, marked with 500/20 in black ink.
Bottle:
Package sizes: 6, 10, 20, 30, 60, 100, 180, or 500 modified-release tablets.
The bottles contain a silica gel desiccant (to keep the tablets dry). Do not ingest the desiccant packet.
or
The bottles contain a silica gel desiccant in the screw cap (to keep the tablets dry).
Box with aluminum blisters:
Package sizes: 10, 20, 30, 60, or 100 modified-release tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Grünenthal Pharma, S.A.
Doctor Zamenhof, 36
28027 Madrid
Spain
Manufacturer:
Grünenthal GmbH
Zieglerstraße 6
52078 Aachen
Germany
This medicine is authorized in the Member States of the European Economic Area under the following names:
Member State | Medicine name |
Germany, Austria, Belgium, Bulgaria, Spain, Estonia, Finland, Netherlands, Ireland, Italy, Latvia, Lithuania, Luxembourg, Norway, Portugal, United Kingdom (Northern Ireland), Romania, Sweden | Vimovo |
Date of last revision of the leaflet:July 2023
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of VIMOVO 500 mg/20 mg MODIFIED-RELEASE TABLETS in October, 2025 is around 25.63 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.